Your browser is no longer supported. Please, upgrade your browser.
AVEO AVEO Pharmaceuticals, Inc. monthly Stock Chart
AVEO Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.54 Insider Own0.14% Shs Outstand25.81M Perf Week-12.23%
Market Cap153.87M Forward P/E- EPS next Y-1.68 Insider Trans- Shs Float24.78M Perf Month-5.11%
Income-28.50M PEG- EPS next Q-0.38 Inst Own34.00% Short Float4.11% Perf Quarter13.03%
Sales5.90M P/S26.08 EPS this Y238.20% Inst Trans-12.95% Short Ratio2.40 Perf Half Y-31.81%
Book/sh1.56 P/B3.45 EPS next Y-12.00% ROA-48.00% Target Price- Perf Year-29.21%
Cash/sh2.41 P/C2.24 EPS next 5Y- ROE-103.70% 52W Range2.23 - 10.71 Perf YTD-13.82%
Dividend- P/FCF- EPS past 5Y15.60% ROI-1.20% 52W High-49.77% Beta1.37
Dividend %- Quick Ratio4.30 Sales past 5Y9.70% Gross Margin- 52W Low141.24% ATR0.35
Employees19 Current Ratio4.30 Sales Q/Q-86.00% Oper. Margin- RSI (14)40.04 Volatility6.02% 6.08%
OptionableYes Debt/Eq0.34 EPS Q/Q-131.80% Profit Margin- Rel Volume0.99 Prev Close5.41
ShortableYes LT Debt/Eq0.34 Earnings- Payout- Avg Volume424.65K Price5.38
Recom1.20 SMA20-6.57% SMA50-9.04% SMA200-0.89% Volume419,566 Change-0.55%
Nov-09-20Initiated Stifel Buy $9
Aug-13-20Initiated SVB Leerink Outperform $7
Sep-11-19Upgrade H.C. Wainwright Neutral → Buy $1.75
Feb-04-19Downgrade B. Riley FBR Buy → Neutral $5 → $1
Feb-01-19Downgrade H.C. Wainwright Buy → Neutral $1
Jan-04-19Initiated Robert W. Baird Outperform
Nov-13-17Initiated B. Riley FBR, Inc. Buy $5
May-19-16Initiated Piper Jaffray Overweight $1.70
Mar-30-16Initiated FBR Capital Outperform $3
Mar-09-15Upgrade RBC Capital Mkts Underperform → Sector Perform $2 → $3
Dec-16-13Downgrade RBC Capital Mkts Sector Perform → Underperform $5 → $2
May-03-13Upgrade Stifel Sell → Hold
May-03-13Downgrade RBC Capital Mkts Outperform → Sector Perform $15 → $6
May-03-13Downgrade Canaccord Genuity Buy → Hold $2
Dec-21-12Reiterated RBC Capital Mkts Outperform $18 → $15
Nov-14-12Initiated Stifel Nicolaus Sell
May-04-12Reiterated RBC Capital Mkts Outperform $24 → $19
May-13-11Upgrade MP Advisors Underperform → Market Perform $11 → $20
Nov-30-10Initiated RBC Capital Mkts Outperform $24
Nov-29-10Initiated MP Advisors Underperform $8
Nov-10-20 07:00AM  
Nov-09-20 06:35PM  
Nov-05-20 07:00AM  
Nov-03-20 12:30PM  
Oct-19-20 07:00AM  
Oct-16-20 09:58AM  
Oct-14-20 10:03AM  
Oct-13-20 08:36AM  
Oct-09-20 12:30PM  
Oct-08-20 11:37AM  
Oct-07-20 10:49AM  
Oct-06-20 08:54AM  
Sep-22-20 08:34AM  
Sep-15-20 04:05PM  
Sep-14-20 08:07AM  
Sep-09-20 12:42PM  
Sep-08-20 01:11PM  
Sep-04-20 12:52PM  
Sep-03-20 07:00AM  
Aug-18-20 12:00PM  
Aug-11-20 08:48AM  
Aug-10-20 07:35PM  
Aug-06-20 12:30PM  
Aug-05-20 04:05PM  
Jul-01-20 09:16AM  
Jun-19-20 04:05PM  
Jun-16-20 10:38PM  
Jun-15-20 04:05PM  
Jun-04-20 07:01PM  
Jun-02-20 11:41AM  
Jun-01-20 01:15PM  
May-30-20 11:31AM  
May-29-20 07:05AM  
May-27-20 04:05PM  
May-12-20 08:50AM  
Apr-30-20 09:55AM  
Apr-29-20 02:30PM  
Apr-15-20 11:30AM  
Mar-31-20 04:05PM  
Mar-30-20 11:54AM  
Mar-27-20 04:40PM  
Mar-17-20 11:52AM  
Mar-16-20 05:25PM  
Mar-05-20 12:30PM  
Feb-26-20 12:00PM  
Feb-19-20 09:08AM  
Feb-13-20 08:05AM  
Feb-12-20 04:26PM  
Jan-28-20 11:14AM  
Jan-27-20 07:00AM  
Jan-06-20 07:00AM  
Dec-20-19 05:34PM  
Dec-12-19 11:30AM  
Dec-04-19 07:00AM  
Nov-26-19 07:00AM  
Nov-19-19 07:00AM  
Nov-18-19 06:00AM  
Nov-15-19 08:57AM  
Nov-13-19 01:14PM  
Nov-12-19 07:00AM  
Nov-08-19 10:08AM  
Nov-07-19 11:08AM  
Nov-06-19 11:00AM  
Nov-04-19 07:00AM  
Nov-01-19 11:30AM  
Oct-22-19 09:32AM  
Oct-17-19 08:58AM  
Oct-16-19 09:00AM  
Sep-30-19 07:00AM  
Sep-26-19 07:00AM  
Sep-23-19 07:00AM  
Sep-13-19 09:36AM  
Sep-11-19 11:40AM  
Sep-10-19 11:18AM  
Sep-07-19 09:30AM  
Aug-29-19 09:13AM  
Aug-09-19 11:29AM  
Aug-08-19 08:35AM  
Jul-30-19 10:38AM  
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical needs. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase III TIVO-3 trial of tivozanib for the treatment of RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, acute myeloid leukemia, and pancreatic cancer; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. AVEO Pharmaceuticals, Inc. has collaboration and license agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Kirin Co., Ltd. It has a clinical collaboration with AstraZeneca PLC to evaluate IMFINZI (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SANDELL SCOTT D10% OwnerJun 19Buy5.251,428,5717,499,9983,952,958Jun 22 05:30 PM
Sonsini Peter W.10% OwnerJun 19Buy5.251,428,5717,499,9983,952,958Jun 22 05:31 PM
MAKOWER JOSHUA10% OwnerJun 19Buy5.251,428,5717,499,9983,952,958Jun 22 05:29 PM
Makhzoumi Mohamad10% OwnerJun 19Buy5.251,428,5717,499,9983,952,958Jun 22 05:28 PM
BASKETT FOREST10% OwnerJun 19Buy5.251,428,5717,499,9983,952,958Jun 22 05:26 PM
Florence Anthony A. Jr.10% OwnerJun 19Buy5.251,428,5717,499,9983,952,958Jun 22 05:27 PM
Growth Equity Opportunities Fu10% OwnerJun 19Buy5.251,428,5717,499,9983,952,958Jun 22 05:26 PM